Monoclonal Antibody Against Cervical Carcinoma
Author Information
Author(s): C.C. Yuan, L.C. Tsai, S.C. Hsu, H.T. Ng, S.J. Tsai, H.M. Chen, M.W. Hung, C.K. Ho, D.M. Ho, T.J. Gill, III
Primary Institution: Veterans General Hospital, Taipei, Taiwan; University of Pittsburgh Medical Center, Pennsylvania, USA
Hypothesis
The study aims to establish and characterize a monoclonal antibody that recognizes a specific antigen present in cervical carcinoma cells.
Conclusion
The monoclonal antibody Cx-99 shows high specificity for cervical carcinoma and may be useful for diagnostic applications.
Supporting Evidence
- The antibody Cx-99 recognized an antigen present in 100% of the 37 squamous cell carcinomas examined.
- Most cervical squamous cell carcinomas showed extensive staining with the antibody.
- The antigen was also detected in the culture medium of cervical cancer cell lines.
- The study suggests that the antigen's expression is linked to oncogenesis.
Takeaway
Researchers created a special antibody that can find cancer cells in the cervix, which could help doctors diagnose cervical cancer better.
Methodology
The antibody was produced by immunizing mice with cervical carcinoma tissues and screening for reactivity against various cell lines and tissues.
Limitations
The study does not address the potential for cross-reactivity with other tissues or the long-term stability of the antibody in clinical settings.
Participant Demographics
The study involved human cervical carcinoma tissues collected from patients undergoing surgery.
Want to read the original?
Access the complete publication on the publisher's website